Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Austria
  4. Wiener Boerse
  5. Marinomed Biotech AG
  6. News
  7. Summary
    MARI   ATMARINOMED6

MARINOMED BIOTECH AG

(MARI)
  Report
Real-time Estimate Tradegate  -  01:56:03 2023-02-07 pm EST
47.55 EUR   +1.17%
2022Austria's Marinomed Biotech Secures US Patent for Solubilization Technology
MT
2022Marinomed Biotech Ag : Marinomed Biotech receives US Patent approval for the Marinosolv« technology and invests in a series of new patents
EQ
2022Marinomed Biotech AG Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Marinomed Biotech : Conference Call Invitation Results Q3 2022

11/11/2022 | 07:32am EST

Invitation: Conference Call on 21 November 2022

10.00 a.m. CET (9.00 a.m. GMT) presenting Marinomed`s nine months 2022 results

Korneuburg, Austria, 11 November 2022 - Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics is pleased to invite you to its international conference call (held in English language) to present its nine months 2022 results on 21 November 2022 at 10.00 a.m. CET (9.00 a.m. GMT). Your dialogue partners will be Dr. Andreas Grassauer (CEO), Dr. Eva Prieschl-Grassauer (CSO) and Pascal Schmidt (CFO).

Pre-registration:

Participants may pre-register and will receive dedicated dial-in details to access the call easily and quickly: https://services.choruscall.de/DiamondPassRegistration/register?confirmationNumber=5664951 &linkSecurityString=c86650428

Logging in to the call:

Once registered (see above), please use the information provided in the confirmation email. We recommend dialing in a few minutes prior to the call.

Concurrent presentation:

Slide Show Participants' Link: https://www.c-meeting.com/web3/join/MLD3PK2LN4AYV8

The Marinomed presentation window will open at the beginning of the conference. The webcast does not support audio (please follow the instructions above for audio). The presentation can be downloaded c. 15 minutes before the conference call from the Company's website: Financial publications :: Marinomed

Both the press release and the report on the nine months 2022 results will be published on

21 November 2022 at 7.45 a.m. CET / 6.45 a.m. GMT and will be available on the Company's website in the sections: Corporate News :: Marinomedand Financial publications :: Marinomed

If you have any further questions, please do not hesitate to contact:

Marinomed Biotech AG

International Media Contact

Stephanie Kniep, Investor Relations

MC Services AG

Hovengasse 25, 2100 Korneuburg, Austria

Dr. Brigitte Keller, Dr. Regina Lutz

E-Mail: ir@marinomed.com

T +49 89 210228 0

T: +43 2262 90300 226

UK: Shaun Brown

M: +44 7867 515 918

E-Mail: marinomed@mc-services.eu

Disclaimer: This invitation does not constitute or contain any investment advice. It is not and shall not be construed as an offer, invitation, recommendation or solicitation to sell, issue, purchase or subscribe for any securities in any jurisdiction or to enter into any transaction.

Disclaimer

Marinomed Biotech AG published this content on 11 November 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 November 2022 12:31:03 UTC.


ę Publicnow 2022
All news about MARINOMED BIOTECH AG
2022Austria's Marinomed Biotech Secures US Patent for Solubilization Technology
MT
2022Marinomed Biotech Ag : Marinomed Biotech receives US Patent approval for the Marinosolv« t..
EQ
2022Marinomed Biotech AG Reports Earnings Results for the Nine Months Ended September 30, 2..
CI
2022Marinomed Biotech : Investor Presentation Q3 2022
PU
2022Marinomed Biotech AG reports increase in revenues for the first 9 months 2022 and signi..
EQ
2022Marinomed Biotech : Conference Call Invitation Results Q3 2022
PU
2022Marinomed Biotech : Investor Presentation LSX InvÇ$tival November 2022
PU
2022Marinomed Biotech : First successful year on the market for Marinomed's Solv4U technology ..
PU
2022First successful year on the market for Marinomed's Solv4U technology partnerships
EQ
2022Marinomed Biotech : to attend several upcoming investor and industry conferences
PU
More news
Financials
Sales 2022 11,6 M 12,5 M 12,5 M
Net income 2022 -6,82 M -7,32 M -7,32 M
Net Debt 2022 16,0 M 17,1 M 17,1 M
P/E ratio 2022 -9,50x
Yield 2022 -
Capitalization 71,1 M 76,3 M 76,3 M
EV / Sales 2022 7,48x
EV / Sales 2023 5,39x
Nbr of Employees 42
Free-Float 61,7%
Chart MARINOMED BIOTECH AG
Duration : Period :
Marinomed Biotech AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MARINOMED BIOTECH AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 47,00 €
Average target price 84,35 €
Spread / Average Target 79,5%
EPS Revisions
Managers and Directors
Andreas Grassauer Chairman-Management Board & CEO
Pascal Schmidt Chief Financial Officer
Simon Jules Nebel Chairman-Supervisory Board
Eva Prieschl-Grassauer Chief Scientific Officer
Helmut Baranyovszki Head-Operations
Sector and Competitors